ストックスクリーナーアプリを入手
13.51
0.00%
0.00
アフターアワーズ：
13.51
前日終値:
$13.51
開ける：
$13.54
24時間の取引高:
1.03M
Relative Volume:
0.64
時価総額：
$1.51B
収益：
-
当期純損益:
$-137.25M
株価収益率:
-7.1481
EPS:
-1.89
ネットキャッシュフロー:
$-121.97M
1週間 パフォーマンス:
+0.82%
1か月 パフォーマンス:
+27.33%
6か月 パフォーマンス:
+25.44%
1年 パフォーマンス:
+76.37%
1日の値動き範囲:
$12.80
$13.91
1週間の範囲:
$12.77
$14.01
52週間の値動き範囲:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
名前
Oric Pharmaceuticals Inc
セクター
電話
(650) 388-5600
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
13.51 | 1.51B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-11-20 | 開始されました | Evercore ISI | Outperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-10-31 | 開始されました | Wells Fargo | Overweight |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-02-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 開始されました | Wedbush | Outperform |
| 2023-03-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Perform |
| 2022-04-04 | アップグレード | Citigroup | Neutral → Buy |
| 2022-03-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-03-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-13 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-06 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-19 | 開始されました | Citigroup | Neutral |
| 2020-05-19 | 開始されました | Guggenheim | Buy |
| 2020-05-19 | 開始されました | JP Morgan | Overweight |
| 2020-05-19 | 開始されました | Jefferies | Buy |
すべてを表示
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
Is ORIC’s ESOP Shelf And Narrower Quarterly Loss Altering The Investment Case For ORIC (ORIC)? - simplywall.st
ORIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP - MarketBeat
Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs - MarketBeat
ORIC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Uncovering a 57% Upside Potential in Biotech - DirectorsTalk Interviews
ORIC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ORIC Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell: Dominic Piscitelli Sells 52,000 Shares of ORIC Pha - GuruFocus
Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals Insider Sold Shares Worth $702,686, According to a Recent SEC Filing - marketscreener.com
Oric Pharmaceuticals CFO Dominic Piscitelli Sells 52,000 Shares - TradingView
ORIC (ORIC) CFO exercises options and sells 52,000 shares in 10b5-1 trades - Stock Titan
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade - Finviz
Trading the Move, Not the Narrative: (ORIC) Edition - Stock Traders Daily
Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst - MarketBeat
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC) - The Globe and Mail
ORIC: Phase III prostate cancer trial and key data updates position both programs for potential market impact - TradingView
ORIC: Phase 3 and key data updates for two oncology programs aim to drive differentiation and growth - TradingView
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright - Yahoo Finance
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway - simplywall.st
H.C. Wainwright raises ORIC Pharmaceuticals price target on trial progress - Investing.com Australia
H.C. Wainwright Maintains Buy on ORIC (ORIC Pharmaceuticals, Inc.) Feb 2026 - Meyka
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Data And US$264 Million Capital Raise - Yahoo Finance
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating - GuruFocus
ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating | ORIC Stock News - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.9% Higher Following Earnings Beat - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Price Target Raised to $25 by H - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals (ORIC) Analyst Rating Reaffirmed by Wedbush - GuruFocus
Oric Pharmaceuticals' (ORIC) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Oric Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oric Pharmaceuticals Launches New 2026 ATM Share Program - TipRanks
ArTara Therapeutics, Inc. announces that the company's research and development pipeline is progressing smoothly, and key clinical trials are advancing according to the established schedule. - Bitget
Oric Pharmaceuticals files new $200 million at-the-market offering prospectus By Investing.com - Investing.com South Africa
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Oric Pharmaceuticals Inc. (ORIC) has announced the launch of an equity offering plan. - Bitget
Oric Pharmaceuticals files new $200 million at-the-market offering prospectus - Investing.com
ORIC's 2025 Milestones Pave Way for Future Breakthroughs - GuruFocus
ORIC Plans Key Milestones for Rinzimetostat and Enozertinib by 2 - GuruFocus
ORIC Pharmaceuticals (NASDAQ: ORIC) renews $200M ATM offering - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Oric Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ORIC: Lead oncology programs advanced to late-stage trials; $245M raised; cash runway into 2028 - TradingView
ORIC Pharmaceuticals Reports Promising Phase 1b Data for Rinzimetostat and Enozertinib, Completes $264 Million Funding Round - Quiver Quantitative
ORIC Pharmaceuticals (NASDAQ: ORIC) boosts 2025 cash runway with $264M raise - Stock Titan
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates - GlobeNewswire
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 85% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Will ORIC Pharmaceuticals Inc. stock gain from government policiesWeekly Investment Summary & Capital Protection Trading Alerts - mfd.ru
Aug Highlights: What are the future prospects of ORIC Pharmaceuticals Inc2025 Institutional Moves & Daily Growth Stock Tips - baoquankhu1.vn
Venrock funds report 5.8% ORIC (ORIC) ownership stake in latest filing - Stock Titan
Oric Pharmaceuticals Inc (ORIC) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):